Literature DB >> 6983824

Epidemiology of amyotrophic lateral sclerosis.

J F Kurtzke.   

Abstract

Motor neuron disease (MND) is used in this paper as the generic label, encompassing the clinical variants of amyotrophic lateral sclerosis (ALS), progressive myelopathic muscular atrophy (PMMA), and progressive bulbar palsy (PBP). ALS is limited to instances of anterior horn cell plus pyramidal tract involvement. When only anterior horn cell lesions are inferred, either PMMA or PBP is used, depending on the levels of involvement; when both cord and brain stem are affected. PBP is the designation. Mortality data on MND have been available for a number of countries since 1949. The coding used under international rules has varied considerably over this interval. Before 1969, hereditary muscular atrophies were included. Since 1979, no subdivision by type of MND is possible. International death rates for MND have all been rather close to 1 per 100,000 population per year, though perhaps nearer to 1.4 on the average in recent years. There has been an increasing proportion of MND deaths coded to ALS between 1949 and 1977. There is no notable geographic variation among countries, nor within countries such as the U.S. and Denmark. A slight upward trend in death rates over time in the U.S. is matched by a slight decrease in Denmark. Death rates from all sources indicate a male preponderance for ALS or MND as a whole, at about 1.5 to 1, male to female. There is also a consistent predilection by age, with few deaths under age 50 or so and a clear maximum in age-specific death rates at about age 70. This holds for both sexes. In the U.S., there is also a white-nonwhite difference, with a ratio of about 1.6:1 but with age and sex differences similar to whites. Average annual incidence rates from among white occidental populations range mostly between 0.6 and 1.8 per 100,000 population for MND and about 0.8 and 1.5 per 100,000 for ALS. Again a male predilection is seen. There is a clear maximum in age-specific incidence rates at about age 65 in all surveys except that of Rochester, Minnesota, where the age-specific rate for those 75+ years of age is apparently higher than that for those age 65 to 74. Incidence rates, then, are quite similar one land to another. A reported deficit in Mexico may reflect case-selection bias. An excess among Filipinos on Hawaii seems more a function of population age-distributions than a true racial or ethnic difference. Prevalence rates from outside the Orient range from about 1 to 7 per 100,000 population for MND and about 2 to 7 for ALS. Those surveys more likely to be reasonably complete provide ALS prevalence rates of about 4 to 6, and an overall estimate of ALS prevalence of some 5 per 100,000 population is a reasonable figure. In the Orient, most of the MND prevalence rates fall within the same range as in the occident, except for two areas of the Kii peninsula of southern Honshu, Japan, where the reported prevalence rates are some 100 to 200 per 100,000 population. These cases are similar to the Guamanian ALS, both clinically and pathologically...

Entities:  

Mesh:

Year:  1982        PMID: 6983824

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  17 in total

1.  Energy intake and amyotrophic lateral sclerosis.

Authors:  Mark P Mattson; Roy G Cutler; Simonetta Camandola
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease.

Authors:  R J Guiloff; D J Eckland; C Demaine; R C Hoare; K D MacRae; S L Lightman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

Review 3.  The Role of Sex and Sex Hormones in Neurodegenerative Diseases.

Authors:  Elisabetta Vegeto; Alessandro Villa; Sara Della Torre; Valeria Crippa; Paola Rusmini; Riccardo Cristofani; Mariarita Galbiati; Adriana Maggi; Angelo Poletti
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 4.  ER stress and unfolded protein response in amyotrophic lateral sclerosis.

Authors:  Kohsuke Kanekura; Hiroaki Suzuki; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2009-01-30       Impact factor: 5.590

5.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

6.  Inequalities in cervical cancer screening in Eastern Europe: perspectives from Bulgaria and Romania.

Authors:  Irina Todorova; Adriana Baban; Anna Alexandrova-Karamanova; Janet Bradley
Journal:  Int J Public Health       Date:  2009       Impact factor: 3.380

7.  Linear longitudinal decline in fractional anisotropy in patients with amyotrophic lateral sclerosis: preliminary results.

Authors:  Joshua P Nickerson; Christopher J Koski; Andrew C Boyer; Heather N Burbank; Rup Tandan; Christopher G Filippi
Journal:  Klin Neuroradiol       Date:  2009-05-23

Review 8.  Flightless flies: Drosophila models of neuromuscular disease.

Authors:  Thomas E Lloyd; J Paul Taylor
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

9.  Neurofilament phosphorylation is enhanced in cultured chick spinal cord neurons exposed to cerebrospinal fluid from amyotrophic lateral sclerosis patients.

Authors:  T N Nagaraja; M Gourie-Devi; A Nalini; T R Raju
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Racial differences in the etiology of dementia and frequency of Alzheimer lesions in the brain.

Authors:  S M de la Monte; G M Hutchins; G W Moore
Journal:  J Natl Med Assoc       Date:  1989-06       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.